PEspeaks

Mar 31, 2015
FDA is under pressure to moderate oversight of pharma advertising and promotion, writes Jill Wechsler.
Mar 30, 2015
Steve Smith provides an advocates account of last month's Rare Disease Week on Capitol Hill.
Mar 29, 2015
A controversial FDA proposal to alter the process for making changes to approved drug labels has drawn opposition and support in equal measure, writes Jill Wechsler.
Mar 24, 2015
Albert Wertheimer, PhD, MBA, Professor of Pharmaceutical Economics at Temple University and a member of Pharm Exec's Editorial Advisory Board, shows how the simple matter of a drug shortage is not a simple matter at all.
Mar 17, 2015
The word ‘centric’ by definition means one, as in focused on a single entity. Yet, in today’s life sciences industry, companies are customer-centric and patient-centric and physician-centric — combined. It's counterintuitive…if not overwhelming, writes Lisa Barbadora
Mar 15, 2015
The Securities and Exchange Commission (SEC) is focusing more on the accuracy and timeliness of biopharma company financial filings, particularly those related to regulatory actions involving FDA, writes Jill Wechsler.
Mar 15, 2015
The EU’s proposed new study on off-label prescribing is just another way of kicking the issue into the long grass, writes Reflector.
Pharmaceutical Executive: Mar 15, 2015
Congress, Obama offer strategies to reduce regulatory roadblocks to new breakthroughs.
Mar 11, 2015
In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes PharmExec Editorial Advisory Board member Cliff Kalb.
Mar 11, 2015
Rohit Sood outlines five critical factors for companies entering this blossoming market.